09:27 AM EST, 11/11/2024 (MT Newswires) -- Aptevo Therapeutics ( APVO ) said Monday that a phase 1 trial of ALG.APV-527 to treat solid tumors has met the trial endpoint of adequate exposure, safety, tolerability and biological activity.

"The interim results from phase 1 trials of ALG.APV-527 are showing encouraging outcomes, particularly in terms of safety and disease stability in the trial patients who were refractory to multiple previous therapies," Thomas Marron, the trial's lead investigator, said in a statement.

Price: 0.2648, Change: +0.01, Percent Change: +2.64